Regulatory Updates
Sep 18, 2026•1 min read
FDA Approves Teva Olanzapine/Fluoxetine Combination (ANDA077528)
FDA has approved Teva Pharmaceuticals' ANDA077528 for an oral capsule combining olanzapine and fluoxetine, with several dosage strengths, as of Feb 26 2021.
Regulatory Updates
Sep 8, 2026•1 min read
FDA Approves ANDA 076392 for Mefloquine Hydrochloride
The FDA has approved ANDA 076392 for Mefloquine Hydrochloride oral tablets (250 mg) manufactured by Teva Pharmaceuticals, sponsor BARR.
Regulatory Updates
Aug 30, 2026•1 min read
FDA Approves PROGLYCEM (Diazoxide) Oral Suspension – NDA 017453
The FDA approved PROGLYCEM, an oral suspension of diazoxide (50 mg/mL) from Teva Pharmaceuticals, under application NDA 017453.